Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

James C. Greenwood


Jim Greenwood is president and CEO of the Biotechnology Industry Organization, 1201 Maryland Ave. SW, Suite 900, Washington, DC 20024, tel. 202.962.9200.
Articles
Prescribing Caution for Biosimilars
April 2, 2013
By: James C. Greenwood

Sound policies are needed to govern the substitution of interchangeable biologics.
Intellectual Property as the Foundation of Innovation
December 2, 2010
By: James C. Greenwood

Supportive public policy is needed in order for innovation to flourish.
Delivering on the Promise of Biotechnology
April 2, 2010
By: James C. Greenwood

The BIO convention, and healthcare reform, could re-energize biotech.
Healthcare Reform Requires Room for Innovation
January 2, 2010
By: James C. Greenwood

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.
Progress Made on the Path to Biosimilars
October 2, 2009
By: James C. Greenwood

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.
Biotechnology in 2009
May 2, 2009
By: James C. Greenwood

The president of BIO proposes the ingredients needed for industry growth.
Industry Leaders Debate Follow-on Biologics Pathway
May 2, 2009
By: James C. Greenwood , Kathleen Jaeger

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
50%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
17%
Raw material supply problems
17%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here